Lead Compass Investment

Wellmarker Bio is a biotechnology company dedicated to the development of innovative cancer therapeutics. It leverages its extensive experience in research and development to create biomarker-based drugs aimed at addressing unmet medical needs in various cancers, including colon, lung, and liver cancer. Wellmarker Bio operates a comprehensive drug development institute that encompasses departments for target discovery, drug discovery, medicinal chemistry, and CMC (chemistry, manufacturing, and controls). Collaborating with the Asan Medical Center in Seoul, South Korea, the company focuses on overcoming resistance to existing therapies through the identification of predictive biomarkers and the creation of first-in-class drugs. Its mission is to provide advanced treatment options that enhance patient outcomes and quality of life.

OxVax Ltd. is a biotechnology company that originated as a spin-out from the University of Oxford. It specializes in the development of an innovative dendritic cell vaccine platform aimed at treating solid tumor cancers. The company's technology utilizes induced pluripotent stem cells (iPSC) to generate CD141+ dendritic cells, a proprietary subset known for their unique properties that enhance their potential as candidates for cancer immunotherapy. By focusing on these specialized cells, OxVax seeks to provide effective treatments for patients battling difficult-to-treat cancers.